YMAB - Y-mAbs Therapeutics Inc Stock Price, Fair Value and News

$8.61

Market Closed as of 16 Sep 2025, 04:00 pm ET

YMAB Stock Valuation Analysis

Valuation

Max Portfolio %

YMAB Price Action

YMAB RSI Chart

YMAB Stock Valuation Analysis

Valuation

Max Portfolio %

YMAB Valuation

YMAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

YMAB Fundamentals

YMAB Revenue

YMAB Earnings

YMAB Profitability

YMAB Investor Care

Revenue & Growth

How Y-mAbs Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2025	88.7M	85.4M	-	-
2024	84.5M	86.5M	84.6M	87.7M
2023	75.0M	85.0M	92.9M	84.8M
2022	40.0M	39.8M	43.4M	65.3M
2021	29.2M	37.6M	46.0M	34.9M
2020	-	-	-	20.8M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

CEO	Mr. Thomas Gad
WEBSITE	ymabs.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	147